Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.38 |
| ▸ | EGFR | P00533 | 4/20 | 0.38 |
| ▸ | BTK | Q06187 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.37 |
| ▸ | ALPL | P05186 | 2/20 | 0.37 |
| ▸ | ALPI | P09923 | 2/20 | 0.37 |
| ▸ | ALPG | P10696 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31223708 | 1.00 | CNR1 (0.38) | CNR1MCHR1EGFRBTKPOLB | |
| SCHEMBL31223700 | 0.87 | BTK (0.40) | CNR1MCHR1EGFRBTKPOLB | |
| SCHEMBL31223346 | 0.87 | BTK (0.40) | CNR1MCHR1EGFRBTKPOLB | |
| SCHEMBL31223492 | 0.85 | BRAF (0.42) | CNR1EGFRBTKPOLBKMT2A | |
| SCHEMBL31223338 | 0.85 | JAK3 (0.41) | BTKKMT2AKCNH2 | |
| SCHEMBL31393838 | 0.85 | JAK3 (0.41) | BTKKMT2AKCNH2 | |
| SCHEMBL29333379 | 0.81 | PIK3CA (0.43) | CNR1MCHR1BTKALPLALPI | |
| SCHEMBL31008634 | 0.81 | PIK3CA (0.43) | CNR1MCHR1BTKALPLALPI | |
| SCHEMBL29334499 | 0.80 | KRAS (0.39) | BTKPOLBP2RX7 | |
| SCHEMBL31223546 | 0.79 | KRAS (0.34) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011291-A1 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2025-01-09 | — | — | US | claimed |
| WO-2024259171-A2 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. (US) | 2024-12-19 | — | — | WO | claimed |
| US-20250011291-A1 | KEAP1 INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011291-A1 | KEAP1 INHIBITORS AND USES THEREOF | KEAP1, NFE2L2, NQO1 | CNR1 4483/4885MCHR1 3135/4885EGFR 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.